PLEASANTON, Calif.,
Jan. 26, 2022 /PRNewswire/
-- 10x Genomics (Nasdaq: TXG) today announced it will report
financial results for the fourth quarter and full year ended
December 31, 2021 after market close
on Wednesday, February 16, 2022. The
company's management will webcast a corresponding conference call
beginning at 1:30 p.m. Pacific Time /
4:30 p.m. Eastern Time to discuss its
results, business developments and outlook.
Live audio of the webcast will be available on the "Investors"
section of the company website at www.10xgenomics.com. The
webcast will be archived and available for replay for at least 45
days after the event.
About 10x Genomics
10x Genomics is a life science
technology company building products to interrogate, understand and
master biology to advance human health. The company's integrated
solutions include instruments, consumables and software for
analyzing biological systems at a resolution and scale that matches
the complexity of biology. 10x Genomics products have been adopted
by researchers around the world including in all of the top 100
global research institutions as ranked by Nature in 2020 based on
publications and all of the top 20 global pharmaceutical companies
by 2020 research and development spend and have been cited in over
3,250 research papers on discoveries ranging from oncology to
immunology and neuroscience. The company's patent portfolio
comprises more than 1,300 issued patents and patent
applications.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, its website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
Contacts
Media:
media@10xgenomics.com
Investors:
investors@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-february-16-2022-301469066.html
SOURCE 10x Genomics, Inc.